The US Food and Drug Administration approved an original PMA for CVRx Inc.’s Barostim Neo baroreflex activation therapy device to treat heart failure based on results from the BeAT HF trial.
Barostim Neo is a pulse generator implanted below the collar bone and a lead connected to the carotid artery. It...